Drug Profile


Alternative Names: (R)-PMPA; GS 1278; PMPA; PMPA-IV

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centre for the AIDS Programme of Research in South Africa; Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer CONRAD; Gilead Sciences; Hanmi Pharmaceutical; National Institute of Allergy and Infectious Diseases
  • Class Adenine nucleotides; Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase I Hepatitis B

Most Recent Events

  • 28 Oct 2016 CTP 260791-Added trial completion info
  • 01 Dec 2015 CONRAD completes a phase II/III trial in HIV infection (Prevention) in South Africa (NCT01691768)
  • 01 Dec 2015 CONRAD completes the FAME 05 trial in HIV infection (Prevention) in USA (NCT02280109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top